Haematologica 2003 - Supplements
Haematologica 2003 - Supplements
Haematologica 2003 - Supplements
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
176<br />
Pro-inflammatory and angiogenic cytokines in multiple<br />
myeloma patients<br />
Jurczyszyn A., Wolska-Smoleñ T., Zawirska D.,Fedak D.,<br />
Naskalski J., Skotnicki A.B.<br />
1. Chair and Department of Hematology, Jagiellonian University,<br />
Cracow, Poland.2. Clinical Biochemistry Department, Jagiellonian<br />
University, Cracow, Poland.<br />
Interleukin-6 (IL-6) is a major growth and survival factor for<br />
myeloma cells and may also play a role in the development of the<br />
bone disease. A soluble form of the IL-6R (sIL-6R) is unusual<br />
amongst soluble cytokine receptors, because it retains biological<br />
activity and acts as an agonist by binding IL-6, associating with<br />
gp130 and allowing signal transduction.<br />
Recent reports pointed that bone marrow angiogenesis is<br />
increased in multiple myeloma patients. It prompted us to<br />
examine plasma concentrations of several cytokines and to<br />
elucidate if any their clinical significance.<br />
We have measured the serum concentration of interleukin-6 (IL-<br />
6), soluble receptor for IL-6 (sIL-6R), vascular endothelial<br />
growth factor (VEGF), soluble vascular endothelial growth factor<br />
receptor (KDR/sVEGF-R2), basic fibroblast growth factor (b-<br />
FGF), tumor growth factor beta-1 (TGF-beta1) and hepatocyte<br />
growth factor (HGF) in 76 patients with multiple myeloma (MM)<br />
and 35 healthy subjects. The circulating serum levels of the<br />
cytokines were measured by Quantikine kit (R&D Systems Inc.,<br />
Minneapolis). Plasma were collected at diagnosis - 29 cases and<br />
during treatment (from 1 month up to 8 years) - 23 cases with<br />
good response to therapy and others with relapsed MM. All<br />
samples were kept frozen at -20°C. Results are reported as<br />
median values (range).<br />
Examined groups<br />
Multiple myeloma Control group<br />
Measured<br />
group<br />
p<br />
cytokines<br />
n x ± SD (minmaxmax)<br />
n x ± SD (min-<br />
IL-6<br />
13,65 ± 42,61 1,04 ± 1,12<br />
65<br />
35<br />
0,006<br />
(pg/ml)<br />
(0 –251,13) (0–3,04)<br />
sIL-6R<br />
37,1 ± 14,2 25,3 ± 6,4<br />
65<br />
35<br />
0,003<br />
(ng/ml)<br />
(15,7 – 78,3) (14,6–38,4)<br />
VEGF<br />
56,8 ± 46,7 49,9 ± 49,9<br />
65<br />
35<br />
NS<br />
(pg/ml)<br />
(5 – 219)<br />
(0 – 176,3)<br />
s VEGF- 7518 ± 2119 8725±1281<br />
65<br />
35<br />